 |
|
Amantadine for Levodopa-Induced Dyskinesias
A 1-Year Follow-up Study
Leo Verhagen Metman, MD;
Paolo Del Dotto, MD;
Kaatje LePoole, BS;
Spiros Konitsiotis, MD;
John Fang, MD;
Thomas N. Chase, MD
Arch Neurol. 1999;56:1383-1386.
Background In a recent acute study, amantadine was found to have antidyskinetic effect against levodopa-induced motor complications in patients with Parkinson disease. The longevity of this effect was not addressed but is of interest in light of the controversy in the literature regarding the duration of amantadine's well-established antiparkinsonian action.
Objective To determine the duration of the antidyskinetic effect of amantadine in advanced Parkinson disease.
Design One year after completion of an acute, double-blind, placebo-controlled, crossover study, patients returned for re-evaluation of motor symptoms and dyskinesias using a nonrandomized, double-blind, placebo-controlled follow-up paradigm.
Setting National Institutes of Health Clinical Center.
Patients Seventeen of the original 18 patients with advanced Parkinson disease complicated by dyskinesias and motor fluctuations participated in this study; 1 was lost to follow-up. Thirteen of the 17 individuals had remained on amantadine therapy for the entire year.
Interventions Ten days prior to the follow-up assessment, amantadine was replaced with identical capsules containing either amantadine or placebo.
Main Outcome Measures Parkinsonian symptoms and dyskinesia severity were scored using standard rating scales, while subjects received steady-state intravenous levodopa infusions at the same rate as 1 year earlier.
Results One year after initiation of amantadine cotherapy, its antidyskinetic effect was similar in magnitude (56% reduction in dyskinesia compared with 60% 1 year earlier). Motor complications occurring with the patients' regular oral levodopa regimen also remained improved according to the Unified Parkinson's Disease Rating Scale (UPDRS-IV).
Conclusion The beneficial effects of amantadine on motor response complications are maintained for at least 1 year after treatment initiation.
From the Experimental Therapeutics Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Md.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(11):1421-1422.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment Options in the Modern Management of Parkinson Disease
Schapira
Arch Neurol 2007;64:1083-1088.
FULL TEXT
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study
Carroll et al.
Neurology 2004;63:1245-1250.
ABSTRACT
| FULL TEXT
Unmet medical needs in Parkinson's disease
Koller and Tse
Neurology 2004;62:S1-8.
ABSTRACT
| FULL TEXT
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease
Thomas et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:141-143.
ABSTRACT
| FULL TEXT
Treatments of Parkinson Disease: Circa 2003
Shults
Arch Neurol 2003;60:1680-1684.
ABSTRACT
| FULL TEXT
Neuroprotection in Parkinson Disease
Simpkins and Jankovic
Arch Intern Med 2003;163:1650-1654.
ABSTRACT
| FULL TEXT
Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine
Verhagen Metman et al.
Neurology 2002;59:694-699.
ABSTRACT
| FULL TEXT
Levodopa strengths and weaknesses
Jankovic
Neurology 2002;58:S19-32.
ABSTRACT
| FULL TEXT
Tremor and dopamine agonists
Elble
Neurology 2002;58:S57-62.
ABSTRACT
| FULL TEXT
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani et al.
Neurology 2001;57:1829-1834.
ABSTRACT
| FULL TEXT
An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
Olanow et al.
Neurology 2001;56:S1-S88.
FULL TEXT
|
